ATF GROUP (PDF) LIMITED AND CONTROLLED ENTITY
A.C.N. 106 213 772

Financial Report
For the year ended
30 June 2013

TABLE OF CONTENTS

ATF GROUP (PDF) LIMITED AND CONTROLLED ENTITY
DIRECTOR'S REPORT

The directors present their report together with the financial report of the consolidated entity consisting of ATF Group (PDF) Limited ("ATF") and the entity it controlled for the financial year ended 30 June 2013 and auditors report thereon. This financial report has been prepared in accordance with Australian equivalents of International Financial Reporting Standards (AIFRS).

Directors Names

The names of the directors in office at any time during or since the end of the financial year are:

Professor Raymond Schinazi appointed 3 August 2007

Jon Lamb appointed 7 November 2007

J. A. (Tony) Wigginton appointed 28 May 2007, resigned 3 August 2007, reappointed 7 September 2007, retired 26 November 2009, reappointed 3 June 2010, resigned May 31 2013

Bernard Romanin appointed 30 May 2008

Directors have been in office since the start of the financial year to the date of this report unless otherwise stated.

Results and review of Operations

The loss of the consolidated group for the year after providing for income tax amounted to $388,019 (2012: $547,224).

Evivar Medical Pty Ltd ("Evivar")

In 2010 the Board had an expectation that its capital raising would be successful and had developed plans to substantially grow the Evivar business. It was confident this could be achieved as it believed that its technology to be world leading.

Unfortunately, all efforts by the Company to raise the funding it required were unsuccessful, whether by reason of the lasting effects of the GFC on capital markets or otherwise. The lack of funding put the Company and Evivar (as the Company was the primary source of its funding) in a difficult position. Without sufficient funds to sustain the continued investment required in Evivar, the Company faced the totally unpalatable possibility of termination by Melbourne Health of its licence of the SeqHepB technology to Evivar (which licence permitted it to operate its business). Termination of the licence would have effectively reduced the value of the Company's investment in Evivar to zero.

In the interests of both its creditors and shareholders, the Board took the decision to sell its investment in Evivar. As a minority investor, the Company persuaded Melbourne Health to join it in the sale process (selling 100% of Evivar offered the opportunity to maximise the potential outcome of the sale process).

When Evivar embarked on the sale process in 2011, little did the ATF Board know that it would be so protracted (over 18 months). In that time, Evivar contacted numerous companies and eventually entered into negotiations for the sale with five parties (which included global diagnostics companies and ASX listed entities).

Offers for the Evivar business were tabled by three of these parties, but none matched either the Board's expectations or were sufficient to enable either the Company or Evivar to meet their financial obligations. Again, in part, the failure of the sale process to meet expectations was the result of a number of factors, including difficult global trading conditions, the commercial pressures faced by the buyers and, in two instances, changes within the businesses of the potential buyers.

In the end, the Board accepted an offer that was significantly below the real value of the Evivar business (but offered an opportunity to at least partially pay the creditors) or place Evivar in administration (with no likelihood of return to the creditors). There were simply no other available alternatives. The outcome was a transaction that was finalised in June 2013.

The purchaser of the Evivar assets was Advanced Biological Laboratories SA (ABL is Healthcare Informatics Company based in Luxembourg).

Significant Changes in State of Affairs
There were no significant changes in the parent entity's and consolidated entity's state of affairs that occurred during the financial year, other than those referred to elsewhere in this financial report.

Principal Activities
The consolidated group is a pro-active investor in Australian personalised health care and therapy management technologies, with a view to facilitating their international development.

No significant change in the nature of these activities occurred during the year.

Events Subsequent to the End of the Reporting Period

Impairment of investment in and sale of Evivar Medical Pty Ltd (Evivar) Assets.
In the interests of both its creditors and shareholders, the Board took the decision to sell its investment in Evivar. As a minority investor, the Company persuaded Melbourne Health to join it in the sale process (selling 100% of Evivar offered the opportunity to maximise the potential outcome of the sale process).

Offers for the Evivar business were tabled by three of these parties, but none matched either the Board's expectations or were sufficient to enable either the Company or Evivar to meet their financial obligations. Again, in part, the failure of the sale process to meet expectations was the result of a number of factors, including difficult global trading conditions, the commercial pressures faced by the buyers and, in two instances, changes within the businesses of the potential buyers. The directors agreed to write off the value of the investment, as financial statement had not yet been issued the impairment of the investment was processed in the June 2010 financial statement.

The Board accepted an offer from Advanced Biological /Laboratories SA (ABL a Healthcare Informatics Company based in Luxembourg), that was significantly below the real value of the Evivar business (but offered an opportunity to at least partially pay the creditors) or place Evivar in administration (with no likelihood of return to the creditors). There were simply no other available alternatives. The outcome was a transaction that was finalised in June 2013.

Evivar was subsequently placed into voluntary liquidation in August 2013. The final distribution of funds from the sale is expected to occur in January 2014. These funds will be used to pay creditors.

Loans to and amounts owing by the Company

Mr Christopher Cuffe extended a loan to the Company of $1.2 million in September 2009. Mr Cuffe converted the loan to shares in December 2012. The accrued interest on the loan at June 30 2013 was $739,647. Mr Cuffe has elected to convert the interest into shares and will be issued 5 million shares as a full and final payment.

Professor Raymond Schinazi extended a loan to the Company of $25,000 in August 2010. The loan amount and accrued interest at June 30 2013 was $28,632. Professor Schinazi has elected to convert the loan and interest to shares and will be issued 193,552 shares as full and final payment.

Mr James Anthony (Tony) Wigginton was entitled to accrued salary and directors fees. Mr Wigginton will be issued 1 million shares as a full and final payment.

Likely Developments

The intention of the Directors moving forward is to identify one or more companies who have interest in acquiring a major holding in the Company (and utilising the PDF status of the Company). These discussions are at various stages, with one group having shown sufficient interest to proceed further. The discussions include a financial consideration which would be expected to provide sufficient capital to clear the Company's liabilities. The Board believes this is the only avenue open to them to return some value, even if it is very small, to the Company's shares. The Directors cannot guarantee that one of these parties will acquire a major holding in the Company but will make their best endeavour to secure the best outcome.

Environmental Issues

The group's operations are not regulated by any significant environmental regulation under a law of the Commonwealth or of a State or Territory.

Dividends Paid, Recommended, and Declared

No dividends were paid or declared since the start of the financial year. No recommendation for payment of dividends has been made.

Information on Directors and Company Secretary

The qualifications, experience and special responsibilities of each person who has been a director at any time during or since the end of the financial year is provided below, together with details of the company secretary as at the year end.

Directors and Company Secretary	***Special Responsibilities***
Professor Raymond F. Schinazi PhD DSc	Chairman and Non Executive Director

Experience and Qualifications

Professor Schinazi has extensive senior management experience in biotech startups, virology, drug discovery and is the founder of several biotechnology companies focusing on antiviral drug discovery and development, including Pharmasset Inc (sold to Gilead Sciences in 2012), Triangle Pharmaceuticals (sold to Gilead Sciences in 2002, Idenix Pharmaceuticals, and RFS Pharma LLC. He has published over 490 peer reviewed papers and seven books and holds more than 100 issued US patents.

He is a pioneer in the development of HIV drugs for the treatment of HIV with more than 94% of individuals on treatment taking at least one of the drugs he invented. He is also the inventor of lamivudine, the first orally approved drug for the treatment of HBV. As the founder of Pharmasset, he was involved in the early development of Sofosbuvir, a drug now approved by the US FDA that can cure HCV infections. Dr Schinazi is the recipient of numerous awards including the 2006 Distinguished Scientist Award from the Hepatitis B Foundation and a Honorary Doctor of Science from Bath University, UK. In 2013, he was inducted as a Charter Fellow into the National Academy of Inventors, and the same year he received the Distinguished Medical Science Award from the National Library of Medicine. He has also served on the Presidential Commission on AIDS. He is currently the Frances Winship Walters Professor of Pediatrics and Chemistry and Director of the Laboratory of Biochemical Pharmacology at Emory University and the Veterans Affairs Medical Center, Atlanta, Georgia in the United States.

Information on Directors and Company Secretary (continued)

Directors and Company Secretary	***Special Responsibilities***
Jon Lamb Dip IMM	Deputy Chairman & Director

Experience and Qualifications
Formerly Chief Executive Officer with Beecham New Zealand, Mr Lamb joined Beecham's marketing division in brand management and new product development, working in South Africa, London, Australia and New Zealand. At age thirty, he was the youngest CEO in the Group and reluctantly left the company after his family decided to settle permanently in New Zealand.

Mr. Lamb has held Directorships of both public and private companies with a focus in the bio-medical field. He has acted as adviser to both the Thai Government and the then newly elected Mandela Government in South Africa as Advisor to the Strategic Planning Council. Mr. Lamb brings a wealth of over thirty years international experience in the pharmaceutical and bio-medical arena ranging from private start up companies to multinational public corporations.

J. A. (Tony) Wigginton *Experience and Qualifications* Mr. Wigginton is a qualified accountant. He has over 35 years experience in the banking and stockbroking industry, both in Australia and overseas. He has held executive management positions with a number of major international banks in Australia, the United States and Asia. He is a director of an ASX listed company and several private companies.	Company Secretary. Director appointed 3 June 2010. (also director from 28 May 2007 to 3 August 2007 and 7 September 2007 retired 26 November 2009), Resigned 31 May 2013
Bernard Romanin Bachelor of Applied Science Grad Dip Marketing	Non-Executive Director - Appointed 30 May 2008

Experience and Qualifications
Mr. Romanin has healthcare experience in Diagnostics, Pharmaceuticals and Medical Devices gained over 30 years in Australia and internationally. He has extensive commercial expertise in sales and marketing, technology licensing and partnership management. He has experience in managing start-up and new market business opportunities. During almost a decade in the USA with Chiron and Novartis, he has directed market development activities to identify, validate and commercialise new opportunities in molecular-based and immuno-based diagnostics in the areas of Infectious Diseases (Hepatitis and HIV/AIDS), Oncology, Cardiovascular Disease and Metabolic Disorders.

Directors' Meetings

The number of meetings of the board of directors and of each board committee held during the financial year and the numbers of meetings attended by each director were:

	Directors Meetings	
	Eligible to attend	Attended
Professor Raymond Schinazi	6	6
Jon Lamb	6	5
J A (Tony) Wigginton	6	6
Bernard Romanin	6	6

Directors' Interests in Shares or Options

Directors' relevant interests in shares of ATF Group (PDF) Ltd or options over shares in the company (or a related body corporate) are detailed below.

Directors' relevant interests in:	Ordinary Shares of AFT Group (PDF) Limited
Professor Raymond Schinazi	1,875,000
Jon Lamb	-
J A (Tony) Wigginton	425,000
Bernard Romanin	-

Share Options

As part of the share placement offer to Christopher Cuffe dated 7 July 2011, 2,600,000 options exercisable at A$0.12 each were offered and accepted, expiring 36 months from date of issue.

Remuneration Report

Remuneration Policies

The board policy for determining the nature and amount of remuneration of key management personnel is agreed by the board of directors as a whole. The board obtains professional advice where necessary to ensure that the company attracts and retains talented and motivated directors and employees who can enhance company performance through their contribution and leadership.

For key management personnel, the company provides a remuneration package that incorporates cash-based and share-based remuneration in lieu of cash. The contract for service between the company and key management personnel are of a continuing basis and terms of which are not expect to change in the immediate future.

The board considers a remuneration policy based on short-term returns may not be beneficial to the long-term creation of wealth by the company for shareholders.

There is no relationship between the company's remuneration policy and the company's performance and remuneration is not dependent on the satisfaction of a performance condition.

Non-executive directors receive fees and do not receive options or bonus payments.

The company determines the maximum amount for remuneration, for directors by resolution. Further details regarding components of directors' and executive remuneration are provided in the notes to the financial statements. The names and position of each person who held the position of director at *any* time during the financial year is provided above. The named executives in the consolidated group who received the highest remuneration for the financial year are:

Remuneration Report (continued)

Executives	*Position*
Professor Raymond Schinazi	Chairman and Non Executive Director
Jon Lamb	Deputy Chairman & Director
J A (Tony) Wigginton	Director & Company Secretary
Bernard Romanin	Non-Executive Director

Directors & Executives Remuneration

	Short-Term		**Post Employment**	**Share-based payments**	**Total**
	Salary Fees	Other	Superannuation	Shares	
2013	$	$	$	$	$
Professor Raymond Schinazi	-	-	-	-	-
Jon Lamb	-	-	-	-	-
J A (Tony) Wigginton	-	-	-	-	-
Bernard Romanin	-	-	-	-	-
	-	-	-	-	-
2012					
Professor Raymond Schinazi	-	-	-	-	-
Jon Lamb	39,215	-	-	-	39,215
J A (Tony) Wigginton	57,210	7,386	-	-	64,596
Bernard Romanin	-	-	-	-	-
	96,425	7,386	-	-	103,811

For the financial year ended 30 June 2013 no wages or directors fees were paid.

Indemnification and insurance of directors, officers and auditors

During or since the end of the year, the consolidated entity has paid premiums in respect of an insurance contract in order to indemnify the directors of the company against liabilities that may arise from their position as officers of the company. Officers indemnified include all directors and executive officers participating in the management of the company.

Further disclosure required under section 300(9) of the corporations law is prohibited under the terms of the contract.

No indemnities have been given or insurance premiums paid, during or since the end of the year, for any person who is or has been an auditor of the company.

Auditor's Independence Declaration

A copy of the auditor's independence declaration under Section 307C of the Corporations Act 2001 in relation to the audit for the financial year is provided with this report.

Proceedings on Behalf of the Company

No person has applied for leave of Court to bring proceedings on behalf of the company or intervene in any proceedings to which the company is a party for the purpose of taking responsibility on behalf of the company for all or any part of those proceedings. The company was not a party to any such proceedings during the year.

Signed in accordance with a resolution of the Board of Directors:

Director ______________________

Bernard Romanin

Director ______________________

Raymond Schinazi

Dated this 19th day of December 2013.

PITCHER PARTNERS

ATF GROUP (PDF) LIMITED AND CONTROLLED ENTITY

AUDITOR'S INDEPENDENCE DECLARATION TO THE DIRECTORS OF ATF GROUP (PDF) LIMITED

In relation to the independent audit for the year ended 30 June 2013, to the best of my knowledge and belief there have been:

(i) No contraventions of the auditor independence requirements of the *Corporations Act 2001*; and

(ii) No contraventions of any applicable code of professional conduct.

M W PRINGLE
Partner

Date 20 December 2013

PITCHER PARTNERS
Melbourne

ATF GROUP (PDF) LIMITED AND CONTROLLED ENTITY
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 30 JUNE 2013

	Notes	Consolidated Group	
		2013	2012
		$	$
Revenue	4	211	42,412
Travelling expenses		(8,283)	(28,127)
Occupancy expenses		-	(21,699)
Administrative expenses		(118,862)	(111,124)
Legal fees		(48,056)	-
Employee benefits		-	(542)
Impairment of loans and investments	5	(54,132)	(166,254)
		(229,122)	(285,334)
Finance Costs	5	(158,897)	(261,890)
Loss before income tax expense		(388,019)	(547,224)
Income tax expense	6	-	-
Loss from operations		(388,019)	(547,224)
Other comprehensive income		(388,019)	(547,224)
Other comprehensive income for the year		-	-
Total comprehensive income for the year		(388,019)	(547,224)
Loss is attributed to:			
Members of the parent		(388,019)	(547,224)
Total comprehensive income attributable to:			
Members of the parent		(388,019)	(547,224)

ATF GROUP (PDF) LIMITED AND CONTROLLED ENTITY
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2013

	Notes	Consolidated Group	
		2013	2012
		$	$
CURRENT ASSETS			
Cash and cash equivalents	7	-	26,000
Other assets	8	84,144	194,832
TOTAL CURRENT ASSETS		84,144	220,832
NON-CURRENT ASSETS			
Other financial assets	9	-	9,874
Property, plant and equipment	11	17,026	20,283
TOTAL NON-CURRENT ASSETS		17,026	30,157
TOTAL ASSETS		101,170	250,989
CURRENT LIABILITIES			
Trade and other payables	12	231,320	159,820
Borrowings	13	797,241	1,833,041
TOTAL CURRENT LIABILITIES		1,028,561	1,992,861
TOTAL LIABILITIES		1,028,561	1,992,861
NET LIABILITIES		(927,391)	(1,741,872)
EQUITY			
Share capital	14	13,308,507	12,106,007
Accumulated losses		(14,235,898)	(13,847,879)
TOTAL EQUITY		(927,391)	(1,741,872)

ATF GROUP (PDF) LIMITED AND CONTROLLED ENTITY
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 JUNE 2013

Consolidated Entity	Notes	Share Capital $	Accumulated Losses $	Total Equity $
Balance as at 1 July 2011		11,514,669	(13,300,655)	(1,785,986)
Loss for the year		-	(547,224)	(547,224)
Total comprehensive income for the year attributable to members of the parent entity		-	(547,224)	(547,224)
Transactions with owners in their capacity as owners and other transfers:				
Shares issued during the year	14	591,338	-	591,338
Total transactions with owners and other transfers		591,338	-	591,338
Balance at 30 June 2012		12,106,007	(13,847,879)	(1,741,872)
Loss for the year			(388,019)	(388,019)
Total comprehensive income for the year attributable to members of the parent entity			(388,019)	(388,019)
Transactions with owners in their capacity as owners and other transfers:				
Conversion of loan funding to shares issued	14	1,200,000	-	1,200,000
Conversion of interest on loan funding to unissued shares	14	2,500	-	2,500
Total transactions with owners and other transfers		1,202,500	-	1,202,500
Balance as at 30 June 2013		13,308,507	(14,235,898)	(927,391)

ATF GROUP (PDF) LIMITED AND CONTROLLED ENTITY
CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 30 JUNE 2013

	Notes	Consolidated Group	
		2013	2012
		$	$
CASH FLOW FROM OPERATING ACTIVITIES			
Receipts from customers		15	843
Payments to suppliers and employees		(99,889)	(240,075)
Interest received		195	1,223
Borrowing costs		(6,783)	(11,492)
Net cash used in operating activities	15	**(106,462)**	**(249,501)**
CASH FLOW FROM INVESTING ACTIVITIES			
Payment for property, plant and equipment			
Loans (to)/from related parties		68,376	(332,278)
Proceeds from disposals of investments (net of amounts held in trust at year end)		-	20,294
Net cash used in investing activities		**68,376**	**(311,984)**
CASH FLOW FROM FINANCING ACTIVITIES			
(Repayment) Proceeds of borrowings		10,853	(25,000)
Proceeds from share issue net of costs		-	591,338
Net cash provided by financing activities		**10,853**	**566,338**
Net (decrease)/increase in cash held		(27,233)	4,853
Cash at beginning of financial year		26,000	21,147
Cash at end of financial year	6,13	**(1,233)**	**26,000**

NOTE 1: STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

These consolidated financial statements and notes represent ATF Group (PDF) Limited and controlled entity ('Consolidated Group' or 'Group').

The separate financial statements of the parent entity, ATF Group (PDF) Limited, have not been presented within the financial report as permitted by amendments made to the Corporations Act 2001 effective as at 28 June 2010

ATF Group (PDF) Limited, the legal parent, is a company limited by shares, incorporated and domiciled in Australia.

The financial report was authorised for issue by the directors as at the date of the directors' report.

Basis of Preparation

The financial statements are general purpose financial statements that have been prepared in accordance with Australian Accounting Standards (including Australian Accounting Interpretations) of the Australian Accounting Standards Board and the Corporations Act 2001.

Australian Accounting Standards set out accounting policies that the AASB has concluded would result in financial statements containing relevant and reliable information about transactions, events and conditions. Compliance with Australian Accounting Standards ensures that the financial statements and notes also comply with International Financial Reporting Standards. Material accounting policies adopted in the preparation of these financial statements are presented below and have been consistently applied unless otherwise stated.

(a) Principles of Consolidation

The consolidated financial incorporate the assets, liabilities and results of entities controlled by ATF Group (PDF) Limited at the end of the reporting period. A controlled entity is any entity over which ATF Group (PDF) Limited has the power to govern the financial and operating policies so as to obtain benefits from its activities.

Where controlled entities have entered or left the group during the year, the financial performance of those entities are included only for the period of the year that they were controlled. A list of controlled entities is contained in Note to the financial statements.

In preparing the consolidated financial statements, all inter-group balances and transactions between entities in the consolidated group have been eliminated in full on consolidation.

Non-controlling interests, being the equity in a subsidiary not attributable, directly or indirectly, to a parent, are shown separately within the Equity section of the consolidated Statement of Financial Position and Statement of Comprehensive Income. The non-controlling interests in the net assets comprise their interests at the date of the original business combination and their share of changes in equity since that date.

(b) Revenue

Revenue from the rendering of a service is recognised upon the delivery of the service to the customers.

Interest revenue is recognised when it becomes receivable on a proportional basis taking in to account the interest rates applicable to the financial assets.

All revenue is stated net of the amount of goods and services tax (GST).

NOTE 1: STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

(c) Cash and Cash Equivalents

Cash and cash equivalents include cash on hand, deposits held at call with banks, other short-term highly liquid investments with original maturities of 3 months or less, and bank overdrafts are shown within short-term borrowings in current liabilities on the statement of financial position.

(d) Property, Plant and Equipment

Each class of property, plant and equipment is carried at cost, where applicable, any accumulated depreciation.

Plant and equipment

Plant and equipment is measured on the cost basis.

The carrying amount of plant and equipment is reviewed annually by directors to ensure it is not in excess of the recoverable amount from those assets.

Depreciation

The depreciable amount of all fixed assets are depreciated over their estimated useful lives to the company commencing from the time the asset is held ready for use.

The depreciation rates used for each class of assets are:

Class of fixed asset	*Depreciation rates*	*Depreciation basis*
Office Equipment	10 to 20%	Diminishing Value
Furniture, fixtures & fittings	7.5 % to 67%	Diminishing Value

Leases

Leases are classified at their inception as either operating or finance leases based on the economic substance of the agreement so as to reflect the risks and benefits incidental to ownership.

Operating leases

Lease payments for operating leases, where substantially all the risks and benefits remain with the lessor, are charged as expenses in the periods in which they are incurred)

(e) Income Tax

The Company (ATF Group (PDF) Limited) is a registered Pooled Development Fund (PDF). The PDF program was established by the Federal Government in 1993 to encourage investment in small and medium-sized Australian enterprises. The PDF Act is administered by the Venture Capital Committee (Committee).

Favourable tax treatment is available for both the Company, and its shareholders: There is no capital gains tax on the sale of shares held by a shareholder in a PDF. Shareholders may elect to treat dividends paid by the company as tax exempt or treat the franked amount of any such dividend as assessable income in order to receive the benefit of the attached franking credits. The Company pays a corporate tax rate of 15% on PDF investment income and 25% on other income.

NOTE 1: STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

(e) Income Tax (continued)

To maintain its status as a PDF, the Company must comply with the regulations imposed by the Pooled Development Funds Act 1992. The Company has to conduct its investment activities in accordance with the following:

- It must invest 65% of its raised capital within five years of the raising;
- It may only invest in new shares in Australian companies;
- It must invest over $500,000 in each investment or, if it invests a lesser sum, take a minimum 10% equity in the investee company;
- Investee companies must have less than A$50 million in total assets;
- The funds invested by the Company must be used to establish an eligible business, to substantially expand production capacity or to substantially expand existing markets of an eligible business.

Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses.

(f) Borrowing Costs

Borrowing costs can include interest, amortisation of discounts or premiums relating to borrowings, ancillary costs incurred in connection with arrangement of borrowing.

Borrowing costs are expensed as incurred.

(g) Impairment of Assets

Assets with an indefinite useful life are not amortised but are tested annually for impairment in accordance with AASB 136. Assets subject to annual depreciation or amortisation are reviewed for impairment whenever events or circumstances arise that indicates that the carrying amount of the asset may be impaired. An impairment loss is recognised where the carrying amount of the asset exceeds its recoverable amount. The recoverable amount of an asset is defined as the higher of its fair value less costs to sell and value in use.

(h) Employee benefits

Liabilities arising in respect of wages and salaries, annual leave and any other employee benefits expected to be settled within twelve months of the reporting date are measured at their nominal amounts based on remuneration rates which are expected to be paid when the liability is settled. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow to be made in respect of services provided by employees up to the reporting date.

Defined contribution superannuation plan

The consolidated entity makes contributions to defined contribution superannuation plans in respect of employee services rendered during the year. These superannuation contributions are recognised as an expense in the same period when the employee services are received.

NOTE 1: STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

(i) Financial Instruments

Classification

Financial assets in the scope of AASB 139 Financial Instruments: Recognition and Measurement are classified as: financial assets at fair value through profit and loss account, loans and receivables, held-to-maturity investments, and available-for-sale financial assets. The classification depends on the purpose for which the investments were acquired. Management determines the classification of its investments at initial recognition.

Financial assets

Investments in unlisted securities where the fair value can be measured reliably are carried at fair value through profit and loss, otherwise they are carried at cost.

Loans and Receivables

Loan and receivables are measured at fair value at inception and subsequently at amortised cost using the effective interest rate method.

Financial Liabilities

Financial liabilities include trade payables, other creditors and loans from third parties including inter-company balances and loans from or other amounts due to director-related entities.

(j) Critical Accounting Estimates and Assumptions

The consolidated group and the parent entity make certain estimates and assumptions concerning the future, which, by definition will seldom represent actual results. The estimates and assumptions that have a significant inherent risk in respect of estimates based on future events, which could have a material impact on the assets and liabilities in the next financial year, are discussed below:

Impairment

The consolidated group and the parent entity assess impairment at each reporting date by evaluating conditions specific to the entities that may lead to impairment of assets. Where an impairment trigger exists, the recoverable amount of the asset is determined. Impairment has been recognised where these assets are not expected to be recoverable (Note 5(b)). In respect of the remaining assets no impairment has been recognised. This is mostly due from the company's invested in or other related parties, or investments in unlisted entities.

(k) Goods and services tax (GST)

Revenue, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Tax Office. In these circumstances the GST is recognised as part of the costs of acquisition of the asset or as part of an item of the expense. Receivables and payables in the statement of financial position are shown inclusive of GST.

Cash flows are presented in the statement of cash flows on a gross basis, except for the GST component of investing and financial activities, which are disclosed as operating cash flows.

(l) Comparative Figures

When required by Accounting Standards, comparative figures have been adjusted to confirm to changes in presentation for the current financial year.

Where the Group has retrospectively applied and accounting policy, made a retrospective restatement of items in the financial statements or reclassified items in its financial statements, an additional statement of financial position as at the beginning of the earliest comparative period will be disclosed

NOTE 2: GOING CONCERN

The financial report has been prepared on a going concern basis, which contemplated continuity of normal business activities and the realisation of assets and settlement of liabilities in the ordinary course of business.

The consolidated group incurred a loss from ordinary activities of $388,019 for the year ended 30 June 2013, and as at that date the consolidated group's total liabilities exceeded total assets by $927,391. The parent entity's current liabilities exceeded total assets by $927,391 as at 30 June 2013.

The consolidated group and the parent entity have incurred substantial losses. In order for the consolidated group and the parent entity to continue trading they are reliant on the following types of funding:

- Raising funds from existing shareholders;
- Raising funds from new shareholders through Prospectus Offers; and
- Generating cash inflows from the sale of their investments.

The intention of the Directors moving forward is to identify one or more companies who have interest in acquiring a major holding in the Company (and utilising the PDF status of the Company). These discussions are at various stages, with one group having shown sufficient interest to proceed further. The discussions include a financial consideration which would be expected to provide sufficient capital to clear the Company's liabilities. The Board believes this is the only avenue open to them to return some value, even if it is very small, to the Company's shares. The Directors cannot guarantee that one of these parties will acquire a major holding in the Company but will make their best endeavour to secure the best outcome.

In addition the sale of the Evivar assets occurred in June 2013. Evivar was subsequently placed into voluntary liquidation in August 2013. The final distribution of funds from the sale is expected to occur in January 2014. These funds will be used to pay creditors.

As such there is uncertainty as to whether the consolidated group and the parent entity will be able to continue as a going concern and therefore whether they will be able to realise their assets and extinguish their liabilities in the normal course of business and at the amounts stated in the financial report.

NOTE 3: PARENT INFORMATION

The following information has been extracted from the books and records of the parent and has been prepared in accordance with Australian Accounting Standards.

	2013	2012
	$	$
STATEMENT OF FINANCIAL POSITION		
ASSETS		
Current Assets	84,044	220,732
Non-current Assets	17,126	30,257
TOTAL ASSETS	101,170	250,989
LIABILITIES		
Current Liabilities	1,028,561	1,992,861
TOTAL LIABILITES	1,028,561	1,992,861
	(927,391)	(1,741,872)
EQUITY		
Share Capital	13,308,507	12,106,007
Retained earnings	(14,235,898)	(13,847,879)
TOTAL EQUITY	(927,391)	(1,741,872)
STATEMENT OF CONPREHENSIVE INCOME		
Total loss	(388,019)	(547,224)
	-	-
Total comprehensive loss	(388,019)	(547,224)

		Consolidated Group	
		2013	2012
		$	$
NOTE 4: REVENUE			
-interest received			
• related parties		-	30,824
• Other persons		195	1,223
-other income			
• Gain on disposal of non-current investment		-	9,522
• Miscellaneous income		16	843
Total revenue		211	42,412

NOTE 5: LOSS BEFORE INCOME TAX

Loss before income tax from continuing operations includes the following specific expenses

(a) Expenses			
Remuneration of the auditor			
• Auditing or reviewing the financial statement		30,500	30,500
Interest expenses on financial liabilities not at fair value through profit and loss			
• External		158,897	261,890
Total finance costs		158,897	261,890
Depreciation of non-current assets			
• Plant and equipment		3,257	4,109
Rental expense		-	21,699

(b) Significant items

The following significant revenue and expense items are relevant in explaining the financial performance:

Impairment of irrecoverable loans	(a)	44,258	145,378
Impairment of investments	(b)	9,874	20,876
		54,132	166,254

(a)The impairment relates to investments in loans made to, related companies, being Evivar Medical Pty Ltd which have been deemed as irrecoverable and therefore are impaired

(b)The impairment of investments relates to fair value adjustment to share held in Hunter Immunology

	Note	Consolidated Group	
		2012	2011
		$	$
NOTE 6: INCOME TAX EXPENES			
The components of tax expense comprise			
Income tax expense attributed to loss		-	-

The group and parent entity's taxable income was $Nil as at balance date as both had incurred significant tax losses

Future income tax benefits not brought to account, the benefits of which will be realised if the conditions for deductibility set out in the accounting policies note occur

		2012	2011
Timing differences		1,040,668	1,037,274
Tax Losses		2,720,865	2,614,782
		3,761,533	3,652,056

NOTE 7: CASH AND CASH EQUIVALENTS

		2012	2011
CURRENT			
Cash at bank and on hand		-	26,000
		-	26,000

NOTE 8: TRADE AND OTHER RECEIVABLES

		2012	2011
CURRENT			
Related party loans	(a)	72,557	185,091
Sundry debtors		11,587	9,741
Total current trade and other receivables		84,144	194,832

(a) All loans are non-interest bearing

NOTE 9:OTHER FINANCIAL ASSETS

		2012	2011
NON-CURRENT			
Shares in unlisted company – at fair value		-	9,874
Total non-current trade and other receivables		-	9,874

NOTE 10: CONTROLLED ENTITIES

Controlled Entities Consolidated	Country of incorporation	Percentage Owned (%)* 2013	2012
Subsidiaries of ATF Group(PDF) Limited:			
Global Therapy Management Limited	Australia	100	100

*Percentage of voting power in proportion to ownership

100 ordinary shares at $1 each were issued to ATF Group (PDF) Limited, representing the entire share capital of this company

NOTE 11: PLANT AND EQUIPMENT

	Note	Consolidated Group 2013 $	2012 $
Office Equipment			
At cost		24,251	24,251
Less accumulated depreciation		(12,922)	(10,703)
		11,329	13,548
Furniture, fixtures and fittings			
At cost		25,266	25,266
Less accumulated depreciation		(19,569)	(18,531)
		5,697	6,735
Total Plant and Equipment		17,026	20,283

(a)Movement in carrying amounts

Movement in the carrying mounts for each class of property plant and equipment between the beginning and the end of the current financial year	Furniture Fixtures & Fittings $	Office Equipment $	Total $
Consolidated Group:			
Balance at 1 July 2011	8,146	16,246	24,392
Depreciation expense	(1,411)	(2,698)	(4,109)
Carrying amount at 30 June 2012	6,735	13,548	20,283
Depreciation expense	(1,038)	(2,219)	(3,257)
Carrying amount at 30 June 2013	5,697	11,329	17,026

NOTE 12: TRADE AND OTHER PAYABLES

	Note	Consolidated Group 2013 $	Consolidated Group 2012 $
CURRENT			
Unsecured trade payables		138,205	63,504
Sundry payables and accrued expenses		93,115	93,316
		231,320	159,820
(a)Financial liabilities at amortised cost classified as trade and other payables			
Trade and other payables			
• Total current		231,320	159,820
Financial liabilities as trade and other payables		231,320	159,820

NOTE 13: BORROWINGS

	Note	2013 $	2012 $
CURRENT			
• Bank overdraft		1,233	-
• Unsecured - Loan from directors		10,853	-
• Unsecured other loans		16,875	-
• Secured - Loan payable	(a)	739,648	1,808,041
• Secured - Loan from directors	(b)	28,632	25,000
		797,241	1,833,041

(a) The loan payable relates to a loan from Cherryoak Investments Pty Ltd (ATF C&N Family Trust) (Lender). The loan will bear interest at 15% per annum and is payable on termination. The Lender has converted the principle of $1,200,000 into 10,000,000 ordinary fully paid shares in ATF Group (PDF) Limited. The lender is converting the balance into 5,000,000 ordinary shares. Refer Note 18.

The loan is secured by a share mortgage (accompanied by deposit of the share certificate and a blank transfer executed by ATF) over all the ordinary fully paid shares in Evivar registered in the name of and held beneficially by ATF.

(b) The director loan relates to a loan from Raymond Schinazi. The term of the loan is 120 days from 14 October 2010, and bears interest at the aggregate of the Base Rate from time to time plus a margin of 50 basis points per annum. The loan is to be converted to shares. Refer Note 18.

NOTE 14: ISSUED CAPITAL

	Note	Consolidated Group 2013 $	Consolidated Group 2012 $
Issued and paid up capital			
94,036,033 (2012 : 84,036,033) fully paid ordinary shares	(a)	13,306,007	12,106,007
Unissued shares			
1,000,000 (2012 : NIL) shares granted but not issued	(b)	2,500	-
		13,308,507	12,106,007

NOTE 14: ISSUED CAPITAL (continued)

(a) Ordinary Shares	2013	2012
	No	No
At the beginning of the reporting period	84,036,033	84,036,033
Shares issued during year		
• 20 December 2012	10,000,000	-
At the end of the reporting period	94,036,033	84,036,033

On 20 December 2012 the company issued 10,000,000 ordinary shares at $0.12 each called to 12 cents.

(a) Fully Paid Ordinary Shares	$	$
At the beginning of the reporting period	12,106,007	11,514,669
Shares issued during year	1,200,000	625,000
Brokerage on issue of shares	-	(33,662)
At the end of the reporting period	13,306,007	12,106,007

(b) Movement in unissued shares		No	No
At the beginning of the reporting period		-	-
Shares granted but not issued	(c)	1,000,000	-
At reporting date		1,000,000	-

		$	$
At the beginning of the reporting period		-	-
Shares granted but not issued during year	(c)	2,500	-
At reporting date		2,500	-

(c) The company has proposed that an ex-gratia payment be offered to its previous director in recognition of accrued salary and directors fees from previous year.

The ex-gratia payment will be in the form of a share issue as follows:

- Tony Wigginton 1,000,000 shares @ 0.0025 cents totally $2,500. The issue of these will be made as soon as practicable.

Ordinary shares participate in dividends and the proceeds on winding up of the parent entity in proportion to the number of shares held.

At shareholders meetings each ordinary share is entitled to one vote when a poll is called, otherwise each shareholder has one vote on a show of hands

Options

As part of the share placement offer to Christopher Cuffe dated 7 July 2011, 2,600,000 options exercisable at A$0.12 each were offered and accepted, expiring 36 months from date of issue.

	2013	2012
	$	$
NOTE 15: CASH FLOW INFORMATION		
(a) Reconciliation of cash flow from operations with loss from ordinary activities after income tax		
Loss from ordinary activities after income tax	(388,019)	(547,224)
Non-cash flows in loss from ordinary activities:		
Depreciation	3,257	4,109
Impairment of related party loans	44,258	145,383
Capitalised borrowing costs	152,114	250,398
Profit on disposal of investments	-	(9,521)
Impairment of investments	9,874	20,876
Shares granted but not issued	2,500	-
Changes in assets and liabilities:		
(Increase)/decrease in other assets	(1,946)	(6,370)
Increase/(decrease) in trade and other payables	71,500	(107,152)
Cash flows from operations	(106,462)	(249,501)

NOTE 16: RELATED PARTY TRANSACTIONS

Directors and Executives Compensation

(a) Details of Key Management Personnel

(i) Directors

Professor Raymond Schinazi	Chairman - Non Executive Director – Appointed 3 August 2007
Jon Lamb	Deputy Chairman - Executive – Appointed 7 November 2007
J.A. (Tony) Wigginton	Director – Executive - Appointed 28 May 2007, resigned 3 August 2007, reappointed 7 September 2007, resigned 26 November 2009 and was reappointed 3 June 2010, resigned 31 May 2013
Bernard Romanin	Director – Non Executive - Appointed 30 May 2008

NOTE 16: RELATED PARTY TRANSACTIONS (Continued)

Directors & Executives Remuneration

	Short-Term		Post Employment	Share-based payments	Total
	Salary Fees	Other	Superannuation	Shares	
2013	$	$	$	$	$
Professor Raymond Schinazi	-	-	-	-	-
Jon Lamb	-	-	-	-	-
J A (Tony) Wigginton	-	-	-	-	-
Bernard Romanin	-	-	-	-	-
	-	-	-	-	-
	Salary Fees	Other	Superannuation	Shares	
2012	$	$	$	$	$
Professor Raymond Schinazi	-	-	-	-	-
Jon Lamb	39,215	-	-	-	39,215
J A (Tony) Wigginton	57,210	7,386	-	-	64,596
Bernard Romanin	-	-	-	-	-
	96,425	7,386	-	-	103,811

Directors' Equity Holdings

	Balance 1/07/12	Granted during the year	Balance 30/06/13
	Number	Number	Number
Professor Raymond Schinazi	1,875,000	-	1,875,000
J.A. (Tony) Wigginton	425,000	-	425,000
Jon Lamb	-	-	-
	2,300,000	-	2,300,300

(b) Number of shares held at the balance date by Key Management Personnel or Associated Entities:

There are no key management personnel other than directors.

(c) Related party transactions and balances

Evivar Medical Pty Limited

ATF Group (PDF) Limited owns 45% of the share capital of this company. The investment was written down to Nil (see Note 9). At 30 June 2013, Jon Lamb and Tony Wigginton were directors of both ATF Group (PDF) Limited and Evivar Medical Pty Limited. Evivar Medical Pty Ltd is currently in voluntary administration.

Global Therapy Management Limited (formerly Therapy Management International Limited)

ATF Group (PDF) Limited own 100% of the share capital of this company. At 30 June 2013, Jon Lamb, Tony Wigginton and Professor Raymond Schinazi were directors of both ATF Group (PDF) Limited and Global Therapy Management Limited.

NOTE 17: FINANCIAL INSTRUMENTS

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate as a result of changes in market interest rates.

The consolidated group's and parent entity's exposure to interest rate risks and the effective interest rates of financial assets and financial liabilities are as follows:

Consolidated Group

	Weighted Average Effective Interest Rate	Non-Interest Rate Bearing	Floating Interest Rate	Fixed 1 year or less	Total
2013	%	$	$	$	
Financial assets		-	-	-	-
Cash at bank					
Trade and other receivables		11,587	-	-	11,587
Receivables – other related parties		72,557	-	-	72,557
Total financial assets		**84,114**	**-**	**-**	**84,144**
Financial liabilities					
Bank Overdraft		-	1,233	-	1,233
Trade Creditors		138,205	-	-	138,205
Other Payables		93,115	-	-	93,115
Payable – other related parties		797,241	-	-	797,241
Total financial liabilities		**1,028,561**	**1,233**	**-**	**1,029,794**

2012					
Financial assets					
Cash at bank		-	26,000	-	26,000
Trade and other receivables		9,741	-	-	9,741
Receivables – other related parties		185,091	-	-	185,091
Other financial assets		9,874	-	-	9,874
Total financial assets		**204,706**	**26,000**	**-**	**230,706**
Financial liabilities					
Trade Creditors		63,504	-	-	63,504
Other Payables		96,316	-	-	96,316
Payable – other related parties		-	25,000	1,808,041	1,833,041
Total financial liabilities		**159,820**	**25,000**	**1,808,041**	**1,992,861**

The consolidated group and parent entity's financial instruments consist mainly of deposits with banks, loans to related entities, investments and trade payables. All interest bearing assets and liabilities are due within one year.

Financial risk

The consolidated group and parent entity monitor their financial risk informally on a day to day basis and then formally at monthly Board meetings, where the financial position of the group are discussed in detail.

NOTE 16: FINANCIAL INSTRUMENTS (continued)

Liquidity risk

Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities.

The consolidated entity and parent entity manage liquidity risk by monitoring forecast cash flows and ensuring that adequate cash is available through the raising of equity, refer to commentary at Note 2.

Credit risk

The maximum exposure to credit risk, excluding the value of any collateral or other security, at balance date to recognised financial assets, is the carrying amount, net of any provisions for impairment of those assets, as disclosed in the balance sheet and notes to the financial statements. The consolidated group's and parent entity's exposure is as set out in Note 8 of the financial statements.

NOTE 18: AFTER BALANCE DATE EVENTS

Impairment of investment in and sale of Evivar Medical Pty Ltd (Evivar) Assets.

In the interests of both its creditors and shareholders, the Board took the decision to sell its investment in Evivar. As a minority investor, the Company persuaded Melbourne Health to join it in the sale process (selling 100% of Evivar offered the opportunity to maximise the potential outcome of the sale process).

Offers for the Evivar business were tabled by three of these parties, but none matched either the Board's expectations or were sufficient to enable either the Company or Evivar to meet their financial obligations. Again, in part, the failure of the sale process to meet expectations was the result of a number of factors, including difficult global trading conditions, the commercial pressures faced by the buyers and, in two instances, changes within the businesses of the potential buyers. The directors agreed to write off the value of the investment, as financial statement had not yet been issued the impairment of the investment was processed in the June 2010 financial statement.

The Board accepted an offer from Advanced Biological /Laboratories SA (ABL a Healthcare Informatics Company based in Luxembourg), that was significantly below the real value of the Evivar business (but offered an opportunity to at least partially pay the creditors) or place Evivar in administration (with no likelihood of return to the creditors). There were simply no other available alternatives. The outcome was a transaction that was finalised in June 2013.

Evivar was subsequently placed into voluntary liquidation in August 2013. The final distribution of funds from the sale is expected to occur in January 2014. These funds will be used to pay creditors.

Mr Chris Cuffe extended a loan to the Company of $1.2 million in September 2009. Mr Cuffe converted the loan to shares in December 2012. The accrued interest on the loan at June 30 2013 was $739,647. Mr Cuffe has elected to convert the interest into shares and will be issued 5 million shares as a full and final payment.

Professor Raymond Schinazi extended a loan to the Company of $25,000 in August 2010. The loan amount and accrued interest at June 30 2013 was $28,632. Professor Schinazi has elected to convert the loan and interest to shares and will be issued 193,552 shares as full and final payment.

Mr James Anthony (Tony) Wigginton was entitled to accrued salary and directors fees. Mr Wigginton will be issued 1 million shares as a full and final payment.

NOTE 19: SEGMENT INFORMATION

The company has the following business segments and geographical segments:

(a) Business segments

The company is a pro-active investor in personalised health care and therapy management technologies In Australia with a view to facilitate their international commercial development.

(b) Geographical segments

The company operates predominantly within Australia.

NOTE 20: COMPANY DETAILS

The registered office and principal place of business of the company is c/o:

Minter Ellison Lawyers
Level 23,
South Rialto Towers
525 Collins Street
Melbourne VIC 3000

ATF GROUP (PDF) LIMITED AND ITS CONTROLLED ENTITY

DIRECTORS' DECLARATION

The directors of the company declare that:

1. The financial statements and notes, comprising the Directors' Declaration, Statement of Comprehensive Income, Statement of Financial Position, Statement of Changes in Equity, Statement of Cash Flows and Notes to the Financial Statements, are in accordance with the *Corporations Act 2001*:

   (a) comply with Accounting Standards in Australia and the *Corporations Regulations 2001*; and

   (b) give a true and fair view of the consolidated group and the parent entity's financial position as at 30 June 2013 and of their performance for the financial year ended on that date.

2. In the directors' opinion there are reasonable grounds to believe that the consolidated group and parent entity will be able to pay their debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors.

Director ______________________

Bernard Romanin

Director ______________________

Raymond Schinazi

Dated this day of 19th December 2013.

INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF ATF GROUP (PDF) LIMITED

Report on the Financial Report

We have audited the accompanying financial report of ATF Group (PDF) Limited and controlled entity, which comprises the consolidated statement of financial position as at 30 June 2013, the consolidated statement of comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration of the consolidated entity comprising the company and the entity it controlled at the year's end or from time to time during the financial year.

Directors' Responsibility for the Financial Report

The directors of the company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error. In Note 1, the directors also state, in accordance with Accounting Standard AASB 101 *Presentation of Financial Statements*, that the financial statements comply with *International Financial Reporting Standards*.

Auditor's Responsibility

Our responsibility is to express an opinion on the financial report based on our audit. We conducted our audit in accordance with Australian Auditing Standards. Those standards require that we comply with relevant ethical requirements relating to audit engagements and plan and perform the audit to obtain reasonable assurance about whether the financial report is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial report. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial report, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the company's preparation of the financial report that gives a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the directors, as well as evaluating the overall presentation of the financial report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Independence

In conducting our audit, we have complied with the independence requirements of the *Corporations Act 2001*.

ATF GROUP (PDF) LIMITED
AND CONTROLLED ENTITY
ACN 106 213 772

PITCHER PARTNERS

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF ATF GROUP (PDF) LIMITED

Opinion

In our opinion:

(a) the financial report of ATF Group (PDF) Limited is in accordance with the *Corporations Act 2001*, including:

   (i) giving a true and fair view of the consolidated entity's financial position as at 30 June 2013 and of its performance for the year ended on that date; and

   (ii) complying with Australian Accounting Standards and the *Corporations Regulations 2001*; and

(b) the consolidated financial report also complies with *International Financial Reporting Standards* as disclosed in Note 1.

Emphasis of Matter

Without modifying our opinion, we draw attention to Note 2 in the financial report, which indicates that the consolidated entity incurred a net loss of $388,019 during the year ended 30 June 2013 and, as of that date, the consolidated entity's current liabilities exceeded its total assets by $927,391. These conditions, along with other matters as set forth in Note 2, indicate the existence of a material uncertainty that may cast significant doubt about the consolidated entity's ability to continue as a going concern and therefore, the consolidated entity may be unable to realise its assets and discharge its liabilities in the normal course of business.

Report on the Remuneration Report

We have audited the Remuneration Report included in pages 5 to 6 of the directors' report for the year ended 30 June 2013. The directors of the company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

Opinion

In our opinion, the Remuneration Report of ATF Group (PDF) Limited and controlled entity for the year ended 30 June 2013 complies with section 300A of the *Corporations Act 2001*.

M W PRINGLE
Partner

PITCHER PARTNERS
Melbourne

Date 20 December 2013